Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine in MDS or CMML
In this MEDtalk, Professor Michael Savona from Vanderbilt University shares results from the ASCERTAIN trial investigating the oral combination of decitabine and cedazuridine (DEC-C) for treatment of myelodysplastic syndromes or chronic myelomonocytic leukaemia vs intravenous decitabine. The trial explores the potential of this oral treatment to provide a convenient, effective alternative to traditional intravenous therapies. The results support use of oral decitabine–cedazuridine vs intravenous decitabine.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in